ORAL METHADONE VERSUS SUBLINGUALBUPRENORPHINE FOR TREATMENT OFACUTE OPIOID WITHDRAWAL:A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, CONTROLLED STUDY

DDTC AIIMS0 个研究点目标入组 60 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Inclusion criteria for Cases:
•Male patients between 18 and 60 years of age
•Diagnosis of opioid dependence syndrome according to ICD- 10 criteria
•Dependent on Heroin (any route) or Injection Buprenorphine or Injection Pentazocine
•Should have taken last dose of any opioid within 48 hrs of admission
•Subject willing to give written informed consent

•Exclusion criteria for Cases:
•Dependence on any other substance except Nicotine
•Exposure to either Buprenorphine or Methadone for treatment in preceding 3 months (either detoxification or maintenance)
•Admission to any facility within last 3 month
•Patients requiring other psychotropic medicines (like Benzodiazepines, TCAs, etc.) which can suppress symptoms of opioid withdrawal except hypnotic purposes
•Patients on other medications which can significantly affect serum levels of Buprenorphine or Methadone either prior to admission or during admission
•Any known medical contraindication to either medications
•Co-morbid psychiatric illness
•Patients previously randomized for this study

发起方

DDTC AIIMS